EESC exploratory opinion NAT/913 - Towards the Common Agricultural Policy (CAP) post-2027: for an agricultural sector that meets economic, social and environmental needs
The Covid 19-pandemic has drawn attention to the role of the pharmaceutical industry and to production, availability and affordability of medicines and medicinal products on the European market.
Dependency on critical ingredients, such as active pharmaceutical ingredients (APIs), became obvious when China and India limited exports. According to current data, up to 80% of APIs used in Europe and about 40% of finished medicines sold in Europe come from China or India. The European Union's increasing dependence on API supplies has led to a partial loss of capability to manufacture active substances independently, which poses a potential threat to public health in the countries of the European Union.
Corruption and the lack of rule of law undermine the mutual trust that is underpinning the internal market. This opinion should contribute to bringing attention to how challenges to the rule of law affect the internal market and in particular public procurement.
EU rules on late payments have triggered a reduction in payment delays. However, still more than 60% of businesses in the EU are not paid on time and small and medium-sized enterprises are most affected. The initiative will provide relief to SMEs by revising existing EU payment rules based on available and upcoming evidence to promote a definitive shift towards a culture of “prompt payment".
The Commission is proposing an ambitious revision of the EU pharmaceutical legislation (including a Directive and a Regulation), in order to, inter alia, create a Single Market for medicines, ensure an innovation-friendly framework for research and production and reduce the administrative burden.
EESC opinion on Seeds and other plant and forest reproductive material.